John Matthews

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial

James W. Denham, Allison Steigler, David S. Lamb et al. · The Lancet Oncology · 2011 · 445 citations

Medicine, Oncology, Urology +16

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial

James W. Denham, David Joseph, David S. Lamb et al. · The Lancet Oncology · 2014 · 160 citations

Medicine, Oncology, Urology +16

A <scp>P</scp> hase <scp>III</scp> trial to investigate the timing of radiotherapy for prostate cancer with high‐risk features: background and rationale of the Radiotherapy – Adjuvant Versus Early Salvage ( <scp>RAVES</scp> ) trial

Maria Pearse, Carol Fraser‐Browne, Ian D. Davis et al. · British Journal of Urology · 2014 · 112 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial

James W. Denham, David Joseph, David S. Lamb et al. · The Lancet Oncology · 2018 · 106 citations · Full text

Medicine, Oncology, Urology +16

Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial

James W. Denham, Allison Steigler, Chantelle Wilcox et al. · The Lancet Oncology · 2008 · 96 citations

Medicine, Oncology, Urology +17